AtomVie Global Radiopharma Opens New $160M Facility in Hamilton

HAMILTON, ON, Sept. 4, 2026 /CourierPR/ -- AtomVie Global Radiopharma, a leading Contract Development and Manufacturing Organization (CDMO) in the radiopharmaceutical industry, recently celebrated the grand opening of its new state-of-the-art manufacturing facility in Hamilton, Ontario. The 72,300-square-foot facility, located at 10 Aeropark Boulevard, is the largest single-site CDMO facility in North America dedicated to radiopharmaceutical development, marking a significant milestone in the company's growth.

Invested with over $160 million, the new facility is equipped to handle low-to-high throughput production, increasing AtomVie's manufacturing capacity by more than tenfold. This purpose-built facility is designed to support seamless progression from early development to commercial manufacturing, with customizable spaces tailored to the evolving needs of clients. The facility is expected to house over 200 employees by the end of 2026, reflecting the company's commitment to scaling operations.

AtomVie, a spinout of the Centre for Probe Development and Commercialization (CPDC) at McMaster University, has built its reputation on over a decade of expertise in radiopharmaceutical development. The company has supported more than 70 clinical development and technology transfer programs, manufactured over 1,000 cGMP batches, and delivered more than 4,400 cGMP doses to patients across 28 countries and six continents, achieving a delivery success rate of over 99%. With its new facility, AtomVie is well-positioned to continue scaling production, from clinical development to commercial manufacturing, with its partners.

Bruno Paquin, CEO of AtomVie, highlighted the significance of the grand opening: "This grand opening marks the next chapter in AtomVie's journey and a proud milestone for Canadian innovation in nuclear medicine. Our new facility amplifies our proven track record of reliable global delivery and deep scientific expertise, enabling us to support the development and commercialization of our partners' pipelines. Above all, it advances our purpose of transforming patients' lives by delivering high-quality radiopharmaceuticals to those who need them, all around the world."

Kevin McNeill, Chairman of AtomVie's Board of Directors, echoed Paquin's sentiment, emphasizing the confidence of partners who have supported the company's growth: "AtomVie's new facility inauguration reflects the discipline and dedication of the AtomVie team. This facility solidifies AtomVie's status as a leading radiopharmaceutical CDMO, now built at commercial scale to serve partners with the reliability the field requires."

The grand opening ceremony was attended by government representatives, clients, partners, and members of the radiopharmaceutical community, who toured the facility and witnessed firsthand how AtomVie's expertise is driving the development of the next generation of precision cancer therapies.

AtomVie Global Radiopharma, a global leader in CDMO services, offers a comprehensive range of scientific, technical, regulatory, quality, and logistics services for the development of radiopharmaceuticals from phase I through phase III clinical studies and commercialization. The company currently serves international clients conducting clinical studies in over 28 countries worldwide.